Phase 3 trial results showed that adding pembrolizumab to adjuvant chemotherapy did not improve disease-free survival in most patients with high-risk endometrial cancer. However, patients with mismatch repair-deficient tumors did benefit significantly from immunotherapy. The study included over 1,000 patients with curative surgery, and those in the dMMR subgroup showed a higher disease-free survival rate with pembrolizumab. While the overall results were disappointing, they indicate a potential new standard of care for this subgroup. The trial highlights the importance of identifying biomarkers to determine which patients with gynecological cancers would benefit from immunotherapy. Funding was provided by Merck Sharp & Dohme.
Source link
Mixed Results for Adjuvant Pembro in Endometrial Cancer
